Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $1,465.0 million
Deal Type : Collaboration
AbbVie and EvolveImmune Announce Collaboration to Develop Next-Gen Cancer Biotherapeutics
Details : The collaboration will leverage EvolveImmune’s T-cell engager platform to develop novel antibody-based therapies for solid and hematologic malignancies.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $65.0 million
October 31, 2024
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $1,465.0 million
Deal Type : Collaboration
Lead Product(s) : EV-104
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Pfizer Ventures
Deal Size : $37.0 million
Deal Type : Financing
Details : EvolveImmune intends to use the proceeds to support continued platform and pipeline development including the advancement of its lead program, EV-104, a novel multi-functional T cell engager with integrated CD2 costimulation which conditionally targets U...
Brand Name : EV-104
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : EV-104
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Pfizer Ventures
Deal Size : $37.0 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate the molecular MOA of EvolveImmune’s proprietary costimulatory T cell engager platform, EVOLVE, designed to unleash potent, selective, and integrated T cell costimulation to address unmet needs for the treatment of sol...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : EV104
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EVOLVE-104 (EV104), is a first-in-category therapeutic with potential to address a wide range of patients for the treatment of solid tumors with high selectivity.
Brand Name : EV104
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : EV104
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : EV104
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EV104, includes cannabidiol (CBD) and celecoxib conjugate is a first-in-category therapeutic with potential to address a wide range of solid tumors with high selectivity.
Brand Name : EV104
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 18, 2022
Lead Product(s) : EV104
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?